27-05-2021 дата публикации
Номер: US20210154281A1
Принадлежит:
Described are cell-based cancer vaccines and anti-cancer immunotherapies. The vaccines include isolated tumor cells activated with one or more genotoxic drugs, and, optionally, treated with one or more MK2 inhibitors. The activated cells are highly immunogenic non-proliferative cells, and may be tested for immunogenicity ex vivo for priming T cells by co-incubating the isolated activated cells with dendritic cells and T cells. The vaccines are typically administered into patient's tumor to provide an intratumoral immune activation. Immune checkpoint inhibitor(s) (ICI) may be administered before, during, or after vaccine administration. ICI may be a component of the vaccine. The vaccines confer heightened cytotoxic immune response against the cancer cells, induce tumor regression, and enhance survival from cancer. The vaccines prevent tumor recurrence and induce a long-lasting anti-tumor immunological memory. 1. A composition for treating a patient with cancer , and/or preventing recurrence of the cancer , the composition comprising isolated , activated , primary tumor cells.2. The composition of claim 1 , wherein the cells are live claim 1 , injured cells.3. The composition of claim 2 , wherein the isolated activated cells are activated with one or more genotoxic drugs selected from the group consisting of alkylating agents claim 2 , antimetabolites claim 2 , antimitotics claim 2 , anthracyclines claim 2 , cytotoxic antibiotics claim 2 , and topoisomerase inhibitors claim 2 , and claim 2 , optionally claim 2 , with one or more MAPK-activated protein kinase-2 (MK2) inhibitors.4. The composition of claim 3 , wherein the concentration of drug is sufficient to injure the cells and induce stress signaling claim 3 , but not sufficient to induce maximal cell death of the cells.5. The composition of claim 4 , wherein the genotoxic drug is selected from the group consisting of doxorubucin claim 4 , etoposide claim 4 , mitoxantrone claim 4 , cisplatin claim 4 , oxaliplatin ...
Подробнее